Virological Outcome Measures During Analytical Treatment Interruptions in Chronic HIV-1-Infected Patients


Por: Feher, C, Leal, L, Plana, M, Climent, N, Guardo, AC, Martinez, E, Castro, P, Diaz-Brito, V, Mothe, B, De Quiros, JCLB, Gatell, JM, Aloy, P and Garcia, F

Publicada: 1 dic 2019 Ahead of Print: 3 nov 2019
Resumen:
Background. Analytical treatment interruptions (ATIs) are essential in research on HIV cure. However, the heterogeneity of virological outcome measures used in different trials hinders the interpretation of the efficacy of different strategies. Methods. We conducted a retrospective analysis of viral load (VL) evolution in 334 ATI episodes in chronic HIV-1-infected patients collected from 11 prospective studies. Quantitative (baseline VL, set point, delta set point, VL, and delta VL at given weeks after ATI, peak VL, delta peak VL, and area under the rebound curve) and temporal parameters (time to rebound [TtR], set point, peak, and certain absolute and relative VL thresholds) were described. Pairwise correlations between parameters were analyzed, and potential confounding factors (sex, age, time of known HIV infection, time on ART, and immunological interventions) were evaluated. Results. The set point was lower than baseline VL (median delta set point, -0.26; P < .001). This difference was >1 log10 copies/mL in 13.9% of the cases. The median TtR was 2 weeks; no patients had an undetectable VL at week 12. The median time to set point was 8 weeks: by week 12, 97.4% of the patients had reached the set point. TtR and baseline VL were correlated with most temporal and quantitative parameters. The variables independently associated with TtR were baseline VL and the use of immunological interventions. Conclusions. TtR could be an optimal surrogate marker of response in HIV cure strategies. Our results underline the importance of taking into account baseline VL and other confounding factors in the design and interpretation of these studies.

Filiaciones:
Feher, C:
 Barcelona Inst Sci & Technol, Inst Res Biomed IRB Barcelona, Barcelona, Spain

 Univ Barcelona, Hosp Clin Barcelona, HIVACAT, Infect Dis Dept, Barcelona, Spain

 Univ Barcelona, Hosp Clin Barcelona, August Pi i Sunyer Biomed Res Inst IDIBAPS, HIVACAT,AIDS Res Grp,Retrovirol & Viral Immunopat, Barcelona, Spain

Leal, L:
 Univ Barcelona, Hosp Clin Barcelona, HIVACAT, Infect Dis Dept, Barcelona, Spain

 Univ Barcelona, Hosp Clin Barcelona, August Pi i Sunyer Biomed Res Inst IDIBAPS, HIVACAT,AIDS Res Grp,Retrovirol & Viral Immunopat, Barcelona, Spain

Plana, M:
 Univ Barcelona, Hosp Clin Barcelona, August Pi i Sunyer Biomed Res Inst IDIBAPS, HIVACAT,AIDS Res Grp,Retrovirol & Viral Immunopat, Barcelona, Spain

Climent, N:
 Univ Barcelona, Hosp Clin Barcelona, August Pi i Sunyer Biomed Res Inst IDIBAPS, HIVACAT,AIDS Res Grp,Retrovirol & Viral Immunopat, Barcelona, Spain

Guardo, AC:
 Univ Barcelona, Hosp Clin Barcelona, August Pi i Sunyer Biomed Res Inst IDIBAPS, HIVACAT,AIDS Res Grp,Retrovirol & Viral Immunopat, Barcelona, Spain

Martinez, E:
 Univ Barcelona, Hosp Clin Barcelona, HIVACAT, Infect Dis Dept, Barcelona, Spain

 Univ Barcelona, Hosp Clin Barcelona, August Pi i Sunyer Biomed Res Inst IDIBAPS, HIVACAT,AIDS Res Grp,Retrovirol & Viral Immunopat, Barcelona, Spain

Castro, P:
 Univ Barcelona, Hosp Clin Barcelona, HIVACAT, Infect Dis Dept, Barcelona, Spain

 Univ Barcelona, Hosp Clin Barcelona, August Pi i Sunyer Biomed Res Inst IDIBAPS, HIVACAT,AIDS Res Grp,Retrovirol & Viral Immunopat, Barcelona, Spain

 Hosp Clin Barcelona, Med Intens Care Unit, Barcelona, Spain

Diaz-Brito, V:
 Univ Barcelona, Hosp Clin Barcelona, HIVACAT, Infect Dis Dept, Barcelona, Spain

:
 irsiCaixa AIDS Res Inst, Badalona, Spain

 Hosp Badalona Germans Trias & Pujol, Infect Dis Dept, Badalona, Spain

 Cent Univ Catalonia, Univ Vic, Vic, Spain

De Quiros, JCLB:
 Hosp Gen Univ Gregorio Maranon, HIV Infect Dis Unit, Madrid, Spain

 Inst Invest Sanitaria Gregorio Maranon, Madrid, Spain

Gatell, JM:
 Univ Barcelona, Hosp Clin Barcelona, HIVACAT, Infect Dis Dept, Barcelona, Spain

 Univ Barcelona, Hosp Clin Barcelona, August Pi i Sunyer Biomed Res Inst IDIBAPS, HIVACAT,AIDS Res Grp,Retrovirol & Viral Immunopat, Barcelona, Spain

 ViiV Healthcare, Tres Cantos, Spain

Aloy, P:
 Barcelona Inst Sci & Technol, Inst Res Biomed IRB Barcelona, Barcelona, Spain

 Inst Catalana Recerca & Estudis Avancats, Barcelona, Spain

Garcia, F:
 Univ Barcelona, Hosp Clin Barcelona, HIVACAT, Infect Dis Dept, Barcelona, Spain

 Univ Barcelona, Hosp Clin Barcelona, August Pi i Sunyer Biomed Res Inst IDIBAPS, HIVACAT,AIDS Res Grp,Retrovirol & Viral Immunopat, Barcelona, Spain
ISSN: 23288957





Open Forum Infectious Diseases
Editorial
Oxford University Press, JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA, Estados Unidos America
Tipo de documento: Article
Volumen: 6 Número: 12
Páginas:
WOS Id: 000510170600015
ID de PubMed: 32128329
imagen gold, Green Published

MÉTRICAS